Modulation of HCV replication after combination antiretroviral therapy in HCV/HIV co-infected patients

Area of Science:

• Virology
• Immunology
• Hepatology

Background:

• Hepatitis C virus (HCV) significantly contributes to illness and death in patients with human immunodeficiency virus (HIV) co-infection.
• HIV co-infection accelerates liver disease progression and increases HCV replication.
• The impact of combination antiretroviral therapy (cART) on HCV replication requires deeper investigation.

Purpose of the Study:

• To investigate the effects of effective HIV treatment on HCV replication and liver disease progression in co-infected patients.
• To analyze immune responses and gene expression profiles during cART initiation in HCV/HIV co-infected individuals.

Main Methods:

• A small cohort of HCV/HIV co-infected patients was enrolled in a cART initiation trial.
• Dynamic modeling, immune response evaluation, and microarray profiling were employed.
• Alanine aminotransferase (ALT) levels and HCV viral loads were monitored over time.

Main Results:

• cART led to increased HCV replication and transient elevation of ALT in a subset of patients, indicating hepatic injury.
• Patients with hepatic injury showed stronger HCV-specific immune responses.
• Gene expression changes, including down-regulation of interferon-stimulated genes, were observed early in treatment.
• HCV viral loads eventually declined to levels similar to those in HCV monoinfection.

Conclusions:

• Effective HIV suppression by cART triggers early and late biological events in co-infected patients.
• Transient viral replication and hepatic injury may be linked to early interferon pathway modulation.
• Findings support the recommendation for early antiretroviral therapy in individuals with HCV/HIV co-infection.